The Journal of
Clinical Psychiatry

Depression (MDD)

Article August 30, 2000

Introduction. Norepinephrine: Neurotransmitter for the Millennium

Charles B. Nemeroff, MD, PhD

J Clin Psychiatry 2000;61(suppl 10):3-4

Article Abstract

Introduction. Norepinephrine: Neurotransmitter for the Millennium

Download Free PDF

This PDF is free for all visitors!

Save

Cite

Sponsored

PsychCase360: Choosing the Right Long-Acting Injectable for Patients With Schizophrenia

Explore two real-world schizophrenia cases with Roueen Rafeyan, MD and Melissa Vitale, PMHNP as they discuss challenges with medication adherence, transitioning to long-acting injectables (LAIs), and personalizing treatment strategies to improve patient outcomes.

Vol 86 • 2025 • Number 1

Read the Current Issue

Original Research

Psychological Support in Psychedelic Therapy

Original Research

Long-Term Safety and Efficacy of Esmethadone in MDD

Original Research

Suicidal Behaviors and Obstructive Sleep Apnea

Editorial

A Collaborative Endeavor

Brief Report

Sex Differences in PTSD among US Military Veterans

Clinical and Practical Psychopharmacology

Cannabis Use During Pregnancy and Neuropsychiatric Adverse Outcomes in Children and Young Adults

View current Issue

Related Articles

Article

Brain Zaps

December 20, 2018

Brain zaps are a poorly understood symptom of antidepressant discontinuation, which require further study for both better prevention and treatment. This article describes the characteristics of brain zaps and...

Alexander Papp , Julie A. Onton

Article

ECT in Obsessive-Compulsive-Related Disorders

October 18, 2018

Obsessive-compulsive-related disorders include conditions such as body dysmorphic disorder and skin-picking disorder, as well as tic disorders and self-injurious behaviors. Could electroconvulsive therapy be an effective treatment option? Read...

Samara dos Santos-Ribeiro , Juliana B. de Salles Andrade , Julliana N. Quintas , et al

Article

Glabellar Botulinum for Depression

October 4, 2018

Glabellar injection of botulinum toxin A (BTA) provides a novel and interesting strategy to address shortcomings in the treatment of depression. This study examines the primary clinical trials conducted...

Toren P. Stearns , Mujeeb U. Shad , Gabriela C. Guzman